<DOC>
	<DOCNO>NCT00490321</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness LVADs provide long-term circulatory support patient chronic stage D heart failure ineligible heart transplant . This multi-center , prospective , randomize , control clinical trial , comprise two independent module .</brief_summary>
	<brief_title>VentrAssistTM LVAD Treatment Advanced Heart Failure - Destination Therapy</brief_title>
	<detailed_description>Currently , patient Stage D heart failure transplant candidate treat spectrum therapy , include specialize medical management well mechanical support LVAD approve FDA destination therapy . However , substantial variation therapeutic approach employ treat patient , relatively low number patient receive DT LVAD therapy date . Therefore , VentrAssist DT trial design provide maximal flexibility investigators/clinicians incorporate clinical judgment manage complex patient .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Inclusion Criteria ( The follow general criterion ; detail criterion include study protocol ) : Eligible either VentrAssist FDAapproved DT LVAD LVEF &lt; =25 % Stage D heart failure Ineligible cardiac transplantation Treated standard heart failure therapy Exclusion Criteria ( The follow general criterion ; detail criterion include study protocol ) : Contraindication LVAD implantation Contraindication anticoagulant antiplatelet agent . Preexisting mechanical circulatory support intraaortic balloon pump Therapy investigational intervention time screen A condition , heart failure , would limit survival less 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>VentrAssistTM</keyword>
	<keyword>LVAD</keyword>
	<keyword>End-stage heart failure</keyword>
	<keyword>Cardiomyopathy</keyword>
</DOC>